News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
224,204 Results
Type
Article (5020)
Company Profile (22)
Press Release (219162)
Section
Business (82608)
Career Advice (461)
Deals (15118)
Drug Delivery (8)
Drug Development (19386)
Employer Resources (30)
FDA (3740)
Job Trends (3995)
News (121036)
Policy (7608)
Tag
Academia (291)
Alliances (14849)
Alzheimer's disease (219)
Approvals (3742)
Bankruptcy (94)
Best Places to Work (2953)
Biotechnology (24)
Breast cancer (40)
Cancer (314)
Career advice (391)
Cell therapy (66)
Clinical research (16053)
Collaboration (102)
Compensation (95)
COVID-19 (297)
C-suite (55)
Data (369)
Diabetes (27)
Diagnostics (2009)
Earnings (40215)
Employer resources (31)
Events (37547)
Executive appointments (168)
FDA (3885)
Funding (113)
Gene therapy (30)
GLP-1 (101)
Government (413)
Healthcare (5039)
Infectious disease (309)
Inflammatory bowel disease (22)
Interviews (53)
IPO (7791)
Job creations (1124)
Job search strategy (360)
Layoffs (95)
Legal (2344)
Lung cancer (35)
Manufacturing (36)
Medical device (3850)
Medtech (3851)
Mergers & acquisitions (7398)
Metabolic disorders (85)
Neuroscience (273)
NextGen Class of 2024 (1676)
Non-profit (733)
Northern California (619)
Obesity (42)
Opinion (28)
People (24328)
Phase I (4808)
Phase II (6952)
Phase III (5545)
Pipeline (272)
Postmarket research (632)
Preclinical (1886)
Press Release (66)
Radiopharmaceuticals (105)
Rare diseases (45)
Real estate (1885)
Regulatory (5097)
Research institute (304)
Resumes & cover letters (68)
Southern California (452)
Startups (1013)
United States (4791)
Vaccines (26)
Date
Today (13)
Last 7 days (158)
Last 30 days (689)
Last 365 days (11233)
2024 (11186)
2023 (13373)
2022 (18820)
2021 (19831)
2020 (18379)
2019 (13300)
2018 (10266)
2017 (10089)
2016 (9253)
2015 (12249)
2014 (9695)
2013 (7831)
2012 (8408)
2011 (8873)
2010 (8705)
Location
Africa (182)
Arizona (49)
Asia (11486)
Australia (1606)
California (1257)
Canada (514)
China (41)
Colorado (53)
Connecticut (67)
Europe (24216)
Florida (164)
Georgia (25)
Idaho (23)
Illinois (86)
Indiana (45)
Japan (39)
Kansas (24)
Maine (34)
Maryland (150)
Massachusetts (1018)
Michigan (66)
Minnesota (105)
New Jersey (381)
New York (333)
North Carolina (272)
Northern California (619)
Ohio (38)
Pennsylvania (245)
South America (278)
Southern California (452)
Texas (147)
Utah (34)
Washington State (118)
224,204 Results for "bcr corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Parse Biosciences Launches Evercode Mouse BCR to Support Antibody Engineering and Development for Drug Discovery Applications
December 12, 2024
·
3 min read
Business
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Ascentage Pharma (6855 HK) announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.
June 14, 2024
·
5 min read
Business
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.
June 14, 2024
·
8 min read
Biotech Bay
Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Controls to Ensure Consistent Quality and Optimal Performance of TCR and BCR Profiling Assays
Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Premixed Controls, the first commercially available collection of synthetic mRNA constructs that can serve as universal controls for commercial or home-brewed AIR repertoire sequencing (AIR-Seq, TCR-seq and BCR-seq) assays based on multiplex RT-PCR or 5' RACE PCR techniques.
April 4, 2024
·
3 min read
Biotech Bay
Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Mouse RNA TCR and BCR Kits for Sensitive Immune Repertoire Profiling
Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Mouse RNA TCR and BCR kits.
November 16, 2023
·
3 min read
Pharm Country
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
Specialty cancer diagnostics company Precipio, Inc., announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market.
August 8, 2023
·
5 min read
BioForest
Parse Biosciences Launches Single Cell Immune Profiling Products
Parse Biosciences today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR product line.
May 2, 2024
·
3 min read
Drug Development
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced findings from a Phase 1 study of TERN-701 in Western healthy volunteers.
April 29, 2024
·
10 min read
Genetown
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
Theseus Pharmaceuticals, Inc. announced key anticipated milestones for 2023 and introduced its third development program, a pan-variant tyrosine kinase inhibitor targeting BCR-ABL for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
January 5, 2023
·
9 min read
BioCapital
Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL
Ascentage Pharma announced that updated results from three studies of olverembatinib, the first China-approved third-generation BCR-ABL1 inhibitor, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
June 18, 2024
·
14 min read
1 of 22,421
Next